Knowledge

Comprehensive information, brochures and resources about amyloidosis

Current Research

CARES Study: Anselamimab in AL Amyloidosis

July 2025

Current Research

On July 16, 2025, AstraZeneca presented interim results of the CARES Phase III program for the treatment of AL amyloidosis. In the overall group of patients with advanced disease (Mayo stages IIIa/IIIb), the antibody anselamimab could not significantly improve the primary endpoint – a combined assessment of overall survival and cardiovascular hospitalizations. However, in a predefined subgroup, it showed a clinically relevant extension of survival and fewer cardiac hospitalizations compared to placebo. The 406 study participants received anselamimab or placebo in addition to standard therapy; the treatment was well tolerated. Anselamimab is a novel anti-fibril antibody for the reduction of amyloid deposits; further analyses are ongoing, and the data will be presented at scientific conferences and submitted to regulatory authorities.

Brochures on Transthyretin Amyloidosis with Cardiomyopathy

Our information brochures about Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) are available. These comprehensive guides provide important information about this heart-specific form of amyloidosis.

Brochures on Transthyretin Amyloidosis with Polyneuropathy

Our information brochures about Transthyretin Amyloidosis with Polyneuropathy (ATTR-PN) are available. These comprehensive guides provide important information about this form of amyloidosis.

Brochures on Immunoglobulin Light Chain Amyloidosis

Our information brochures about Immunoglobulin Light Chain Amyloidosis (AL Amyloidosis) are available. These comprehensive guides provide important information about this form of amyloidosis.

Guide for Movement and Training in Amyloidosis

Our brochure offers practical instructions for physical activity and training in amyloidosis. This guide helps those affected improve their quality of life and slow disease progression through adapted exercises.

Information Event 2024

Summary of our information event on November 2, 2024 at Lucerne Cantonal Hospital

Speakers Summary

PD Dr. med. Simon Stämpfli

Co-Chefarzt Kardiologie, LUKS

Neue Behandlungsoptionen Amyloidose

PDF
Dr. med. Rahel Schwotzer

Leitende Oberärztin, Klinik für Medizinische Onkologie und Hämatologie, USZ

Moderne Therapiemöglichkeiten der AL-Amyloidose

PDF
PD Dr. med. Alexander Breitenstein

Leitender Arzt, Klinik für Kardiologie, USZ

Herzschrittmacher bei Amyloidose

PDF
Jennifer Baumgartner, Nina Rezzoli

Dipl. Pflegefachfrauen HF, LUKS

Behandlung Herzinsuffizienz

PDF

Mitbetreuung eines Menschen mit Herzinsuffizienz

PDF

10 Schritte für mehr Lebensqualität bei Herzschwäche

PDF

Additional Resources

Discover more resources and information about amyloidosis.

Questions?

Do you have questions about the content or need further information? Feel free to contact us.

Amyloidosis Switzerland Association

charitable organization

CH-6130 Willisau

info@amyloidose-schweiz.ch

Subscribe to our Newsletter

The latest news, articles, and resources, regularly in your inbox.

© 2024 - 2025 Amyloidosis Switzerland Association. All rights reserved

Website by Grifo Development